A long-standing recognition that information from human genetics studies has the potential
to accelerate drug discovery has led to decades of research on how to leverage genetic and …

Parkinson's disease (PD) is the second most common neurodegenerative disease
characterised by both motor-and non-motor symptoms, including cognitive impairment. The …

Background Statins represent candidates for drug repurposing in Parkinson's disease (PD).
Few studies examined the role of reverse causation, statin subgroups, and dose–response …

Background The genetically predicted lipid-lowering effect of HMGCR or PCSK9 variant can
be used to assess drug proxy effects on kidney function. Methods Mendelian randomization …

Hypertension (HT) is a modifiable risk factor for life-threatening cardiovascular diseases
(CVDs) including coronary artery disease, heart failure, or stroke. Despite significant …

Background: The causal relationship between lipid-lowering drug (LLD) use and lung
cancer risk is controversial, and the role of sphingolipid metabolism in this effect remains …

Organic-anion-transporting polypeptide 1B1 (OATP1B1), encoded by the solute carrier
organic anion transporter family member 1B1 gene (SLCO1B1), is highly expressed in the …

Statins inhibit the 3-hydroxy-3-methylglutaryl-CoA reductase enzyme and are the most
widely used medication for hypercholesterolemia. Previous studies on the metabolite …

Glucose and cholesterol engage in almost all human physiological activities. As the primary
energy substance, glucose can be assimilated and converted into diverse essential …

Advances in technologies to measure a broad set of exposures have led to a range of
exposome research efforts. Yet, these efforts have insufficiently integrated methods that …